Advertisement
Screener

Autolus Therapeutics plc (AUTL) Graph

AUTL Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $45.69M; Cost of revenue $20.47M; Research and development $27.90M; Selling, general and administrative $41.16M.
  • 2026-03-31: Revenue $26.22M; Cost of revenue $24.57M; Research and development $21.21M; Selling, general and administrative $39.95M.
  • 2025-12-31: Revenue $24.29M*; Cost of revenue $25.33M*; Research and development $35.63M*; Selling, general and administrative $35.80M*.
  • 2025-09-30: Revenue $21.19M; Cost of revenue $28.64M; Research and development $27.89M; Selling, general and administrative $36.28M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

AUTL revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.License$17.00KProduct$45.67MRevenue$45.69MCost of revenue$20.47MOperating income-$43.84MOther income, net$181.00KResearch & development$27.90MSelling, general& administrative$41.16MPre-tax income-$38.65MIncome tax$465.00K

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

AUTL revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$45.69MRevenue$45.69MCost of revenue$20.47MOperating income-$43.84MOther income, net$181.00KResearch & development$27.90MSelling, general& administrative$41.16MPre-tax income-$38.65MIncome tax$465.00K

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$45.69M$20.47M$27.90M$41.16M(m)$465.00K-$39.11M
2026-03-31$26.22M$24.57M$21.21M$39.95M(m)$863.00K-$71.60M
2025-12-31$24.29M*$25.33M*$35.63M*$35.80M*(m)-$1.18M*-$90.33M*
2025-09-30$21.19M$28.64M$27.89M$36.28M(m)$532.00K-$79.12M
2025-06-30$20.92M$24.45M$27.43M$30.27M(m)$397.00K-$47.92M
2025-03-31$8.98M$17.95M$26.73M$29.54M(m)$2.23M-$70.16M
2024-09-30$0.00$0.00$40.32M$27.33M(m)$22.00K-$82.09M
2024-06-30$0.00$0.00$36.61M$21.90M(m)$51.00K-$58.27M
2024-03-31$10.09M$0.00$30.67M$18.18M(m)-$8.00K-$52.69M
2023-09-30(m)(m)$32.32M(m)(m)-$21.00K-$45.85M
2023-06-30(m)(m)$33.23M(m)(m)$40.00K-$45.55M
2023-03-31(m)(m)$27.39M(m)(m)-$14.00K-$39.81M
2022-09-30(m)(m)$31.48M(m)(m)-$5.00K-$42.77M
2022-06-30(m)(m)$30.79M(m)(m)-$56.00K-$42.06M
2022-03-31(m)(m)$28.36M(m)(m)-$26.00K-$37.06M
2021-03-31$269.00K(m)$30.73M(m)(m)-$5.72M-$33.27M
2020-09-30(m)(m)$33.55M(m)(m)-$7.87M-$37.31M
2020-06-30$293.00K(m)$31.33M(m)(m)-$7.02M-$32.05M
2020-03-31$338.00K(m)$31.29M(m)(m)-$3.70M-$29.87M
2019-12-31$309.00K*(m)(m)(m)(m)(m)(m)
2019-09-30$297.00K(m)$27.31M(m)$35.62M-$4.60M-$27.25M
2019-06-30$338.00K(m)$26.17M(m)$37.20M-$3.27M-$28.48M
2019-03-31$1.96M(m)$22.57M(m)(m)-$3.42M-$27.18M
2018-12-31$296.00K(m)$17.71M(m)$25.01M-$2.60M-$20.65M
2018-09-30$307.00K(m)$10.10M(m)$17.06M-$2.20M-$12.86M
2018-06-30$443.00K(m)$8.86M(m)$16.52M-$2.22M-$7.65M
2018-03-31(m)(m)(m)(m)(m)(m)-$16.72M
2017-12-31$231.00K(m)$5.56M(m)$8.42M-$1.40M-$7.52M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$71.91M$45.04M$49.11M$81.11M(m)$1.33M-$110.71M
2025-06-30$29.91M$42.40M$54.16M$59.80M(m)$2.62M-$118.08M
2024-06-30$10.09M$0.00$67.28M$40.08M(m)$43.00K-$110.96M
2023-06-30(m)(m)$60.62M(m)(m)$26.00K-$85.36M
2020-06-30$631.00K(m)$62.62M(m)(m)-$10.72M-$61.92M
2019-06-30$2.30M(m)$48.74M(m)$67.36M-$6.70M-$55.66M
2018-06-30$869.00K(m)$20.49M(m)$32.05M-$3.68M-$24.37M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$51.10M$71.04M$82.06M$96.08M(m)$3.15M-$197.20M
2024-09-30$10.09M$0.00$107.61M$67.41M(m)$66.00K-$193.06M
2023-09-30(m)(m)$92.94M(m)(m)$5.00K-$131.21M
2022-09-30(m)(m)$109.81M(m)(m)-$19.25M-$121.89M
2020-09-30(m)(m)$96.16M(m)(m)-$18.58M-$99.23M
2019-09-30$2.60M(m)$76.05M(m)$102.98M-$11.29M-$82.91M
2018-09-30$1.18M(m)$36.15M(m)$49.12M-$7.28M-$44.75M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$75.39M$96.37M$117.69M$131.87M(m)$1.97M-$287.53M
2024-12-31$10.12M$11.39M$138.44M$101.72M(m)$1.53M-$220.66M
2023-12-31$1.70M$0.00$130.48M$46.74M(m)-$19.00K-$208.38M
2022-12-31(m)(m)$117.35M(m)(m)$272.00K-$148.84M
2021-12-31(m)(m)$110.84M(m)(m)$58.00K-$142.10M
2020-12-31(m)(m)$134.89M(m)(m)-$24.16M-$142.09M
2019-12-31$2.91M(m)$105.42M(m)(m)-$15.16M-$123.85M
2018-09-30$1.41M(m)$36.15M(m)$57.53M-$7.28M-$44.75M
2017-09-30$1.69M(m)$16.01M(m)$23.42M-$3.65M-$19.73M
2016-09-30$1.21M(m)$10.44M(m)$14.38M-$1.78M-$12.55M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Entera Bio Ltd. (ENTX)$0.485B
REGENXBIO Inc. (RGNX)United States$0.477B-3.30
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
Prime Medicine, Inc. (PRME)United States$0.557B-3.54
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Allogene Therapeutics, Inc. (ALLO)United States$0.574B-4.33
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Editas Medicine, Inc. (EDIT)United States$0.424B-4.29
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Zura Bio Ltd (ZURA)$0.398B-6.56